This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaelin, W. G. Search for Related Content PubMed PubMed Citation Articles by Kaelin, W. G., Jr.

The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma

Author's Affiliation: Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

Requests for reprints: William G. Kaelin, Jr., Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115. Phone: 617-632-3975; Fax: 617-632-4760; E-mail: William_kaelin{at}dfci.harvard.edu.

Germ line VHL tumor suppressor gene loss-of-function mutations cause von Hippel-Lindau disease, which is associated with an increased risk of central nervous system hemangioblastomas, clear cell renal carcinomas, and pheochromocytomas. Somatic VHL mutations are also common in sporadic clear cell renal carcinomas. The VHL gene product, pVHL, is part of a ubiquitin ligase complex that targets the -subunits of the heterodimeric transcription factor hypoxia-inducible factor (HIF) for polyubiquitylation, and hence, proteasomal degradation, when oxygen is available. pVHL-defective clear cell renal carcinomas overproduce a variety of mRNAs that are under the control of HIF, including the mRNAs that encode vascular endothelial growth factor, platelet-derived growth factor B, and transforming growth factor . In preclinical models, down-regulation of HIF-, especially HIF-2, is both necessary and sufficient for renal tumor suppression by pVHL. These observations are probably relevant to the demonstrated clinical activity of vascular endothelial growth factor antagonists in clear cell renal carcinoma and form a foundation for the testing of additional agents that inhibit HIF, or HIF-responsive gene products, in this disease.

This article has been cited by other articles:

				M. Lee and V. Vasioukhin Cell polarity and cancer - cell and tissue polarity as a non-canonical tumor suppressor J. Cell Sci., April 15, 2008; 121(8): 1141 - 1150. [Abstract] [Full Text] [PDF]

				M. D. Allen and M. Bycroft The solution structure of the ZnF UBP domain of USP33/VDU1 Protein Sci., September 1, 2007; 16(9): 2072 - 2075. [Abstract] [Full Text] [PDF]